Hemp Well Partners Portal

Pet Hemp & CBD Industry Outlook (2025)

Updated:

Snapshot

  • Pet ownership remains massive. Depending on the source, 66–71% of U.S. households own pets; APPA’s 2025 State of the Industry cites ~94 million pet-owning households. APPA press • APPA stats
  • Pet supplements keep growing. U.S. pet supplement sales are generally modeled in the $1.1–$1.3B range for 2024–2025, with mid- to high-single-digit CAGR into the 2030s. See FMI (U.S.) and FMI (global).
  • Pet CBD is still a niche—but expanding. Analyst models vary: 2023–2025 global estimates range from ~$248M to ~$945M today, with ~20–33% CAGR forecasts. Sources: Grand View (global) • Grand View (U.S.)

Market Structure: From Cottage to Curated

Pet hemp/CBD remains fragmented, with a long tail of micro-brands online and a smaller cohort of audited, specialty-retail players (Hemp Well). Estimating U.S. revenue precisely is hard due to: marketplace bans on CBD (e.g., Amazon, Walmart and Target), mixed state rules, and inconsistent labeling/claims among non-audited brands. See Amazon-focused explainers Why Can't I Buy CBD from the Grocery Store or Amazon?

What’s new since 2020: many specialty retailers emphasize NASC-audited suppliers, tighter label/claims governance, and 3rd-party testing. In 2024, a peer-reviewed 90-day canine CBD safety study reported good tolerability in healthy dogs at 5 mg/kg/day—while FDA warning letters continued for non-compliant claims, keeping pressure on quality. Read: Frontiers in Veterinary Science • NASC release.


Regulation & Retail Gateways (2025)

Federal

FDA stance unchanged. The agency has concluded that current food/supplement frameworks are not appropriate for CBD and asked Congress to create a new pathway; enforcement continues on drug-like claims. See FDA statement and FDA CBD page.

Advertising & Platforms

  • Google Ads: limited allowances (e.g., certain FDA-approved CBD and some topicals) via LegitScript certification; with geography-specific restrictions (e.g., CA/CO/PR). Policy overview.
  • Amazon U.S.: still no CBD (ingestible or topical) in 2025; hemp seed products are allowed. See brand policy explainers above.

State & Supply

USDA’s 2024 National Hemp Report shows a small uptick in floral hemp area versus 2022 and experimentation in fiber/seed; acres remain well below 2019 peaks—disciplined sourcing matters. USDA PDF. This shortfall will impact the cost of domestic hempseed oil and powder production.


  • Idaho: Among the strictest states. CBD is generally lawful only when products contain 0.0% THC; delta-8 is illegal. Hempseed foods (e.g., hulled seed, seed oil, protein) remain allowed, but any manufactured hemp product with detectable THC is prohibited.
  • Alabama (2025): The state now regulates consumable hemp: bans on smokable hemp, 21+ age limits, licensing, testing/labeling, and potency caps for psychoactive THC (e.g., per-serving and per-package limits). Retail sale continues under these restrictions but offers no pathway for pet supply retailers to register and sell pet products.
  • Broader pattern: Many states ban or tightly regulate delta-8 and similar hemp-derived THC. Expect more rules around potency caps, age gates, placement (behind the counter/away from minors), and licensing—rather than total prohibitions.
  • What’s next: More legislatures are considering comprehensive frameworks for “intoxicating hemp,” while enforcement and rulemaking are intensifying even where statutes haven’t fully changed. State laws do not always carve out paths for compliant pet products and can cause more regulatory fees and red tape for manufacturers and retailers.
Bottom line: Policy is tightening around intoxicating hemp cannabinoids and a shift toward age-restricted, potency-capped, and location-limited sales which can impact our industry.

Bottom line: until Congress acts, larger retailers should favor hemp-nutrition (no CBD/THC) SKUs for widest acceptance, and reserve CBD for states ready for added compliance.

Demand Drivers (2025)

  • Pet humanization persists (fresh/frozen foods, dermatology & pain Rx growth, vet innovation)—supporting premium add-ons like calming (Calm), mobility (Hip & Joint), and digestive (Immune) supplements. Industry coverage
  • Omnichannel sophistication (Autoship, education content) normalizes supplements, while platform policies keep CBD concentrated in independent pet specialty and DTC.

Who Buys Pet Hemp/CBD (Online Trends)

  • Pet parents managing anxiety (Calm), mobility (Hip & Joint), or skin (Thrive) issues; often multi-pet households.
  • Natural/organic preference; looks for transparent COAs and NASC audit badges.
  • Women remain over-represented across many DTC data sets. Hemp Well internal DTC sales data suggests buyers are ~67.1% female). 

Key Risks & Frictions

  • Regulatory ambiguity: Without a Congressional pathway, CBD labels/claims remain risky—stay conservative and avoid drug claims. FDA CBD page
  • Payments & insurance: CBD merchants can face higher processing/underwriting hurdles; hemp-nutrition SKUs are cleaner.
  • Ad policy volatility: Even “allowed” topicals can be throttled—expect pilot-only media and frequent creative reviews. LegitScript/Google

Strategic Guidance for 2025

Two-lane portfolio

  • Lane A (Max reach): Hemp-nutrition (hemp seed–based) SKUs with no CBD/THC for national retailers and marketplaces.
  • Lane B (Selective): CBD SKUs for specialty/regionally permitted doors with full compliance packets (COAs, cGMP, NASC audit history, claims review).

Compliance stack

NASC membership/audit, batch COAs, cGMP documentation, conservative structure/function language, and retail-ready SOPs (recall & QA). NASC

 

What’s Different From 2020

  • FDA’s position solidified (still no supplement pathway; Congress must act). FDA
  • Google slightly cracked the door for extremely limited CBD ads (topicals/FDA-approved; strict vetting). LegitScript
  • Amazon U.S. continues to ban CBD, keeping genuine CBD in pet specialty/DTC. Explainer
  • Pet ownership stayed elevated; supplements grew; pet-CBD remains small but extremely fast-growing with wide estimate bands. FMI
  • Hemp acreage stabilized below 2019 peaks; sourcing matters. USDA

Market Sizing Note

Why estimates diverge: Analysts differ on what’s counted (CBD vs. hemp seed), geographies (U.S. vs. global), channels (vet/indie/DTC vs. marketplaces that ban CBD), and methods (brand panels vs. retail audits). Recent reports place the global pet-CBD market between ~$250M and ~$1.0B in 2024–2025 with ~20–33% CAGR; the U.S. was ~$90M in 2023 with projections toward ~$575M by 2030 at ~30% CAGR. We use this range comparatively, anchor planning to our audited sell-through + retailer reorders, and disclose sources: Grand View (global) • Grand View (U.S.) • FMI